Abstract:Background: The development of drug resistance and the persistence of leukemia stem cells are major obstacles for the use of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML). The induction of autophagic death in tumor cells represents a new route for leukemia treatment. Our previous study showed that infection of CML cells with oncolytic viruses carrying the autophagy gene Beclin1 downregulated BCR/ABL protein expression and significantly increased the killing effect of the oncolytic viruses on CML cells via autophagy activation. However, the specific molecular mechanisms underlying the regulation of BCR/ABL and Beclin1-dependent CML cell killing remain unclear. Methods: A physical interaction between BCR/ABL and Beclin1 was characterized via GST-pulldown, co-IP and dual-luciferase reporter assays. Cell proliferation was examined via CCK-8 and clone formation assays. The expression levels of the related proteins were measured via Western blotting. Autophagosomes were observed under transmission electron microscopy. Lentiviral vectors carrying Atg7/UVRAG shRNA or the Beclin1 gene were used to modulate the expression levels of the indicated genes. Immunofluorescence were performed to examine colocalization of BCR/ABL and p62/SQSTM1. CD34(+)CD38(-) cells were isolated from bone marrow samples from CML patients via fluorescence-activated cell sorting. Results: In this study, we observed that Beclin1 directly interacts with BCR/ABL. Beclin1 inhibited the activity of the BCR/ABL promoter to downregulate the level of BCR/ABL protein and to promote the downstream colocalization of p62/SQSTM1 and BCR/ABL to autolysosomes for degradation via activation of the autophagy signaling pathway. In CML cell lines, primary cells and CD34(+)CD38(-) leukemia stem cells, Beclin1 overexpression significantly inhibited cell growth and proliferation and induced autophagy. Conclusion: Taken together, our results suggest that autophagy induction via Beclin1 overexpression might offer new approaches for treating TKI-resistant CML and for promoting the clearance of leukemia stem cells, both of which have important clinical implications.

Molecular Mechanisms of Leukemia-Associated Protein Degradation.

Leukemia, an Effective Model for Chemical Biology and Target Therapy

Targeting Oncoproteins for Degradation by Small Molecules in Myeloid Leukemia

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

The Molecular Mechanism of Chronic Myelogenous Leukemia and Its Therapeutic Implications: Studies in A Murine Model

Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation

Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.

Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models.

Dissecting the Molecular Mechanism of Chronic Myelogenous Leukemia Using Murine Models

Recent Advances in Signaling Pathways and Kinase Inhibitors for Leukemia Chemotherapy

Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation Via Distinct Structural Degrons.

The Important Roles of Protein SUMOylation in the Occurrence and Development of Leukemia and Clinical Implications

The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia

Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells

Acute Promyclocytic Leukemia: A Model Of Molecular Target Based Therapy

Targeting Protein Degradation Pathways in Tumors: Focusing on Their Role in Hematological Malignancies

Recent advance of clinically approved small-molecule drugs for the treatment of myeloid leukemia

Targeted Therapy: the New Lease on Life for Acute Promyelocytic Leukemia, and Beyond

3075 – ONCOGENIC DEUBIQUITINATION CONTROLS TYROSINE KINASE SIGNALING AND THERAPY RESPONSE IN ACUTE LEUKEMIA